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Background: Metabolites are genetically and environmentally determined. Consequently, they can be 36 
used to characterize environmental exposures and reveal biochemical mechanisms that link exposure to 37 
disease. To explore disease susceptibility and improve population risk stratification, we aimed to 38 
identify metabolic profiles linked to carcinogenesis and mortality and their intrinsic associations by 39 
characterizing subgroups of individuals based on serum biomarker measurements. We included 13,615 40 
participants from the Swedish Apolipoprotein MOrtality RISk Study who had measurements for 19 41 
biomarkers representative of central metabolic pathways. Latent Class Analysis (LCA) was applied to 42 
characterise individuals based on their biomarker values (according to medical cut-offs), which were 43 
then examined as predictors of cancer and death using multivariable Cox proportional hazards models. 44 
Results: LCA identified four metabolic profiles within the population: (1) normal values for all markers 45 
(63% of population); (2) abnormal values for lipids (22%); (3) abnormal values for liver functioning 46 
(9%); (4) abnormal values for iron and inflammation metabolism (6%). All metabolic profiles (classes 47 
2-4) increased risk of cancer and mortality, compared to class 1 (e.g. HR for overall death was 1.26 48 
(95%CI: 1.16 - 1.37), 1.67 (95%CI: 1.47 - 1.90), and 1.21 (95%CI: 1.05 - 1.41) for class 2, 3, and 4, 49 
respectively). 50 
Conclusion: We present an innovative approach to risk stratify a well-defined population based on 51 
LCA metabolic-defined subgroups for cancer and mortality. Our results indicate that standard of care 52 
baseline serum markers, when assembled into meaningful metabolic profiles, could help assess long 53 
term risk of disease and provide insight in disease susceptibility and etiology 54 
Keywords: 55 







Cancer is a multi-pathway disease, assembled as a heterogeneous and hierarchically organized system, 61 
and still one of the major causes of death worldwide – with an increasing burden given the aging 62 
population (1-3). Cancer data has grown exponentially in the last decade with new advanced 63 
technologies resulting in highly diverse, mixed data types and huge volumes of information (e.g.: 64 
542045 is the number of publications retrieved in PubMed when searching the terms ‘cancer’ AND 65 
‘data’ on August 2017). Due to the nature of this emerged “Big Cancer Data” and the demand for high-66 
sensitive and high-specific biomarkers, there is a need for significant sample sizes and advanced 67 
mathematical and statistical models (4, 5) capable of extracting relevant clinical and biological 68 
information (6, 7). These more systematic-based approaches, replacing single biomarker analyses by 69 
multiple profiling testing, may provide new avenues for biomarker development in cancer diagnosis 70 
and management (8, 9). Recent studies have adopted these integrative approaches assessing multiple 71 
serum markers simultaneously for cancer diagnosis (10-13). Furthermore, the concept of the exposome 72 
has been introduced into the field of cancer epidemiology (14). It refers to every non-genetic exposure 73 
to which an individual is subjected from conception to death (14, 15) . Specifically, metabolites, part of 74 
the internal exposome, are both genetically and environmentally determined and can consequently be 75 
used to characterize environmental exposures and reveal biochemical mechanisms that link exposure to 76 
disease (15-18). Hence, the internal distribution of metabolites and their interactions might help 77 
unravelling cancer susceptibility in a population. 78 
 79 
With the overall goal of identifying statistical methods to stratify individuals based on their underlying 80 
risk of developing cancer and risk of increasing mortality,  we conducted a data driven approach 81 
utilizing standard serum markers available from routine health check-ups to study susceptibility to 82 
cancer and death in a well-defined cohort of 13,615 participants from the AMORIS study 83 
(Apolipoprotein MOrtality RISk) (19, 20).  More specifically, the study was set out to explore 84 
population heterogeneity and cancer susceptibility by investigating serum metabolic profiles using 85 
latent class analysis (LCA). This data reduction method clusters covariates based on models of data 86 
4 
 
distribution probabilities. It allows for evaluation of clusters of biomarkers linked to carcinogenesis and 87 
their intrinsic associations, which ultimately helps us assess their possible role in predicting long-term 88 




Characteristics of the study population 93 
A total of 1,956 individuals (14.37%) developed cancer after at least 3 years of follow-up, including 94 
655 breast and genito-urinary cancers, 330 cases of digestive cancer, 133 cases of respiratory cancers 95 
and 129 lymphatic and hematopoietic cancers during a mean follow-up time for cancer of 16.6 years, 96 
median follow-up time in the cohort of 17.22 years with a minimum of 3.01 years and a maximum of 97 
24.77. 3,158 participants (23.20%) died during a mean follow-up of 17.3 years, comprising 706 cancer-98 
specific deaths. Study population characteristics by cancer status is illustrated in Table 1. 99 
 100 
 101 
Table 1| Characteristics of the study population by cancer status defined at the end of the follow up period. All the serum 102 








   
Mean (SD) 51.91 (14.80) 50.86 (15.00) 58.14 (11.75) 
Under 40 2951 (21.67) 2841 (24.37) 110 (5.62) 
40-50 3550 (26.07) 3148 (27.00) 402 (20.55) 
50-60 3065 (22.51) 2491 (21.37) 574 (29.35) 
Above 60 4049 (29.74) 3179 (27.27) 870 (44.48) 
Sex 
   
Female 7588 (55.73) 6636 (56.92) 952 (48.67) 
Male 6027 (44.27) 5023 (43.08) 1004 (51.33) 
Socio-economics Status 
   
High 6493 (47.69) 5416 (46.45) 1077 (55.06) 
Low 5007 (36.78) 4368 (37.46) 639 (32.67) 
Not employed or missing 2115 (15.53) 1875 (16.08) 240 (12.27) 
Educational Status 
   
High 4313 (33.42) 3688 (33.40) 625 (33.57) 
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Middle 5495 (42.58) 4725 (42.79) 770 (41.35) 
Low 3097 (24.00) 2630 (23.82) 467 (25.08) 
Missing b 710 (5.21) 616 (5.28) 94 (4.80) 
CCI 
   
0 12258 (90.03) 10520 (90.23) 1738 (88.85) 
1 963 (7.07) 807 (6.92) 156 (7.98) 
2 221 (1.62) 188 (1.61) 33 (1.69) 
3+ 173 (1.27) 144 (1.24) 29 (1.48) 
Total Cholesterol (mmol/L) 
  
Mean(SD) 5.82 (1.17) 5.79 (1.18) 6.00 (1.13) 
< 6.50 9774 (71.79) 8453 (72.50) 1321 (67.54) 
≥ 6.50 3841 (28.21) 3206 (27.50) 635 (32.46) 
Triglycerides (mmol/L) 
   
Mean(SD) 1.44 (1.00) 1.43 (1.00) 1.48 (0.93) 
< 1.71 10128 (74.39) 8716 (74.76) 1412 (72.19) 
≥ 1.71 3487 (25.61) 2943 (25.24) 544 (27.81) 
Apolipoprotein A-1 (g/L) 
   
Mean(SD) 1.44 (0.23) 1.44 (0.23) 1.43 (0.23) 
< 1.05 328 (2.41) 278 (2.38) 50 (2.56) 
≥ 1.05 13287 (97.59) 11381 (97.62) 1906 (97.44) 
Apolipoprotein B (g/L) 
   
Mean(SD) 1.22 (0.35) 1.22 (0.35) 1.29 (0.34) 
< 1.50 10902 (80.07) 9431 (80.89) 1471 (75.20) 
≥ 1.50 2713 (19.93) 2228 (19.11) 485 (24.80) 
HDL Cholesterol (mmol/L) 
  
Mean(SD) 1.54 (0.43) 1.54 (0.43) 1.52 (0.43) 
< 1.03 1457 (10.70) 1231 (10.56) 226 (11.55) 
≥ 1.03 12158 (89.30) 10428 (89.44) 1730 (88.45) 
LDL Cholesterol (mmol/L) 
   
Mean(SD) 3.64 (1.06) 3.61 (1.06) 3.82 (1.04) 
< 4.10 9345 (68.64) 8128 (69.71) 1217 (62.22) 
≥ 4.10 4270 (31.36) 3531 (30.29) 739 (37.78) 
Glucose (mmol/L) 
   
Mean(SD) 5.22 (1.53) 5.21 (1.53) 5.30 (1.53) 
< 6.11 12223 (89.78) 10488 (89.96) 1735 (88.70) 
≥ 6.11 1392 (10.22) 1171 (10.04) 221 (11.30) 
Fructosamine (mmol/L) 
   
Mean(SD) 2.09 (0.27) 2.08 (0.27) 2.10 (0.25) 
< 2.6 13184 (96.83) 11291 (96.84) 1893 (96.78) 
≥ 2.6 431 (3.17) 368 (3.16) 63 (3.22) 
GGT (IU/L) * 
   
Mean(SD) 33.21 (48.12) 32.74 (48.09) 36.03 (48.21) 
Normal (<18) 5511 (40.48) 4827 (41.40) 684 (34.97) 
Normal high (18-36) 4983 (36.60) 4236 (36.33) 747 (38.19) 
Elevated (36-72) 2098 (15.41) 1750 (15.01) 348 (17.79) 
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Highly elevated (>72) 1023 (7.51) 846 (7.26) 177 (9.05) 
AST (IU/L) 
   
Mean(SD) 22.84 (19.23) 22.70 (19.60) 23.64 (16.88) 
< 45 13155 (96.62) 11271 (96.67) 1884 (96.32) 
≥ 45 460 (3.38) 388 (3.33) 72 (3.68) 
ALT (IU/L) 
   
Mean(SD) 29.02 (34.35) 28.95 (35.73) 29.41 (24.54) 
< 50 12296 (90.31) 10546 (90.45) 1750 (89.47) 
≥ 50 1319 (9.69) 1113 (9.55) 206 (10.53) 
Albumin (g/L) 
   
Mean(SD) 43.05 (2.82) 43.13 (2.83) 42.58 (2.72) 
<35 28 (0.21) 23 (0.20) 5 (0.26) 
>35 13587 (99.79) 11636 (99.80) 1951 (99.74) 
Leukocytes (109 cells/L) 
   
Mean(SD) 6.52 (1.97) 6.49 (1.96) 6.65 (2.01) 
<10 12956 (95.16) 11106 (95.26) 1850 (94.58) 
≥ 10 659 (4.84) 553 (4.74) 106 (5.42) 
C-Reactive Protein (mg/L) 
   
Mean(SD) 5.86 (15.14) 5.82 (14.25) 6.16 (19.58) 
<10 11858 (87.1) 10193 (87.43) 1665 (85.12) 
10-15 1196 (8.78) 993 (8.52) 203 (10.38) 
15-25 265 (1.95) 223 (1.91) 42 (2.15) 
25-50 200 (1.47) 167 (1.43) 33 (1.69) 
>50 96 (0.71) 223 (0.71) 13 (0.66) 
Iron (µmol/L) * 
   
Mean(SD) 18.13 (5.80) 18.13 (5.83) 18.11 (5.59) 
Low 636 (4.67) 540 (4.63) 96 (4.91) 
Normal 12512 (91.90) 10715 (91.90) 1797 (91.87) 
High 467 (3.43) 404 (3.47) 63 (3.22) 
TIBC (mg/dL) * 
   
Mean(SD) 0.39 (0.11) 0.31 (0.11) 0.31 (0.10) 
Low 4067 (29.87) 3494 (29.97) 573 (29.29) 
Normal 6650 (48.84) 5683 (48.74) 967 (49.44) 
High 2898 (21.29) 2482 (21.29) 416 (21.27) 
Creatinine (µmol/L) * 
   
Mean(SD) 79.65 (16.16) 79.38 (16.37) 81.26 (14.74) 
Low 40 (0.29) 31 (0.27) 9 (0.46) 
Normal 12088 (88.78) 10392 (89.13) 1696 (86.71) 
High 1487 (10.92) 1236 (10.60) 251 (12.83) 
Phosphate (mmol/L) * 
   
Mean(SD) 1.07 (0.17) 1.07 (0.17) 1.05 (0.17) 
Low 95 (0.70) 76 (0.65) 19 (0.97) 
Normal 12796 (93.98) 10948 (93.90) 1848 (94.48) 
High 724 (5.32) 635 (5.45) 89 (4.55) 
Calcium (mmol/L) * 
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Mean(SD) 2.38 (0.09) 2.38 (0.09) 2.38 (0.10) 
Low 191 (1.40) 167 (1.43) 24 (1.23) 
Normal 13195 (96.92) 11300 (96.92) 1895 (96.88) 
High 229 (1.68) 192 (1.65) 37 (1.89) 
Log (triglycerides/HDL) c 
   
mean(SD) (-)0.19 (0.81) (-)0.20 (0.82) (-)0.14 (0.80) 
< 0.5 11197 (82.24) 9618 (82.49) 1579 (80.73) 
≥ 0.5 2418 (17.76) 2041 (17.51) 377 (19.27) 
ApoB/ApoA-I c 
   
mean(SD) 0.87 (0.29) 0.87 (0.29) 0.92 (0.30) 
< 1.00 9584 (70.39) 8347 (71.59) 1237 (63.24) 
≥ 1.00 4031 (29.61) 3312 (28.41) 719 (36.76) 
Life Status 
   
Alive 10457 (76.80) 9385 (80.50) 1072 (54.81) 
Death 3158 (23.20) 2274 (19.50) 884 (45.19) 
Cancer 1956 (14.90) 11659 (0.00) 1956 (100.00) 
 104 
The following abbreviations have been used in Table 1: High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), 105 
Gamma-Glutamyl transferase (GGT), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and Total iron 106 
binding capacity (TIBC). 107 
a Clinically abnormal cut-off values are highlighted for each biomarker. 108 
b The missing values are not included in the percentage of the Educational Status categories 109 
c Ratios are dimensionless 110 
*Clinical cut-offs 111 
The following cut-offs criteria was applied: 112 
GGT reference interval: 113 
Low [GGT < 18 IU/L] 114 
Normal high [18 IU/L ≥ GGT <36 IU/L] 115 
Elevated [36 IU/L ≥ GGT <72 IU/L] 116 
High elevated [GGT ≥ 72 IU/L] 117 
Iron reference interval: 118 
Men [Low ≤ 11, Normal = 11-31, High ≥ 31] 119 
Women [Low ≤ 9, Normal = 9-30, High≥ 30] 120 
TIBC reference interval: 121 
Men [Low ≤ 0.257, Normal = 0.257-0.379, High ≥ 0.379] 122 
Women [Low ≤ 0.246, Normal = 0.246- 0.391, High ≥ 0.391] 123 
Creatinine reference interval: 124 
Men [Low ≤ 60, Normal = 60-100, High ≥ 100] 125 
Women [Low ≤ 45, Norma l= 45-90, High ≥ 90] 126 
Phosphate reference interval: 127 
Men [Low ≤ 0.7, Normal = 0.7-1.4, High ≥ 1.4] 128 
Women [Low ≤ 0.8, Normal = 0.8-1.4, High ≥1.4] 129 
Calcium reference interval per gender by age: 130 
Men 131 
[Age < 40, Low ≤ 2.22, Normal = 2.22-2.60, High ≥2.60] 132 
[Age 40-60, Low ≤ 2.20, Normal = 2.20 -2.59, High ≥2.59] 133 
[Age > 60, Low ≤ 2.19, Normal= 2.19 -2.58, High ≥ 2.58] 134 
Women 135 
[Age < 40, Low ≤ 2.17, Normal = 2.17-2.56, High ≥2.56] 136 
[Age 40-60, Low ≤2.19, Normal = 2.19-2.60, High ≥2.60] 137 




Latent Class Analysis characterizes the study population into four metabolic profiles 140 
LCA was executed using the dichotomized values of the biomarkers to facilitate the biological 141 
interpretation of the results. The Chi-squared distribution criterion for model selection indicated a best 142 
fit model comprehend of four LCA classes, while AIC and BIC stabilized at 4 classes (Figure 1A, Figure 143 
1B) (43). All the criterions did not converge to a local maximum from class 12 onwards. The class 144 
allocation of the observations (individuals), the class conditional probability of each biomarker and the 145 
latent mixing proportions were obtained when running poLCA package in R statistical language. 146 
 147 
Table 2 and Figure 2 outline the LCA-derived classes with the estimated class population proportions, 148 
the class conditional probabilities of belonging to each latent class for each of the biomarkers and the 149 
biological interpretation of the LCA-derived classes. The four mutually exclusive classes characterize 150 
the population in metabolic profiles based on class conditional probabilities: (1) those with probabilities 151 
for all abnormal values of the markers under 0.3; therefore, considered the normal class (63% of 152 
population); (2) those with abnormal values for lipid markers (22%); (3) those with abnormal values 153 
for liver function markers (9%); (4) those with abnormal values for iron and inflammation metabolism 154 
(6%).  155 
A validation of the characterization of the population performed with the Latent class methodology is 156 
outlined in Appendix Table S3. The baseline clinical characteristics of the individuals by LCA-derived 157 
metabolic classes (supplementary Table S3) replicate the results displayed in Table 2 for the class 158 
conditional probabilities.  159 
Table 2| Predicted class memberships of the clinically abnormal biomarkers cut-off values for  160 
the 4 latent classes model. Estimated class population shares for the four different LCA classes. 161 
 162 
LCA-derived Classes Class 1 Class 2 Class 3 Class 4 
% on the population 63% 22% 9% 6% 
Biological interpretation Normal Lipids Liver 
Iron/ 
Inflammation 
ApoB/ApoA-I ≥ 1.00 b 0.1320 0.6840 0.4519 0.2480 
Log (Triglycerides/HDL) ≥ 0.50 
b 
0.0126 0.5436 0.3852 0.1421 
Glucose ≥6.11 mmol/L 0.0342 0.2401 0.2174 0.0919 
Fructosamine ≥ 2.60 mmol/L 0.0039 0.0967 0.0555 0.0280 
ALT ≥ 50 IU/L 0.0051 0.0107 1.0000 0.0291 
GGT Elevated36-72 IU/L 0.0848 0.2532 0.3521 0.1732 
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GGT Highly elevated ≥72 IU/L 0.0240 0.0843 0.4098 0.0619 
AST ≥ 45 IU/L 0.0052 0.0045 0.3168 0.0180 
CRP >10 mg/L 0.0282 0.0715 0.0771 0.2740 
Albumin <35 g/L 0.0007 0.0022 0.0024 0.0114 
Leukocytes ≥ 109 cells/L 0.0265 0.0786 0.0438 0.1344 
Iron low µmol/L 0.0001 0.0040 0.0281 0.5527 
Iron high µmol /L 0.0404 0.0155 0.0712 0.0000 
TIBC low mg/dL 0.2201 0.2807 0.2622 1.0000 
TIBC high mg/dL 0.2438 0.1707 0.2984 0.0000 
Creatinine low µmol /L 0.0022 0.0037 0.0041 0.0051 
Creatinine high µmol /L 0.0822 0.1765 0.1166 0.1116 
Phosphate low mmol/L 0.0078 0.0041 0.0063 0.0098 
Phosphate high mmol/L 0.0425 0.0611 0.0544 0.1110 
Calcium low mmol/L 0.0124 0.0092 0.0099 0.0458 
Calcium high mmol/L 0.0121 0.0253 0.0299 0.0135 
 163 
a High probabilities of the biomarkers to belong to a class are highlighted. 164 
b Ratios are dimensionless 165 
 166 
LCA derived metabolic profiles as cancer and mortality predictors 167 
We then investigated the prediction capabilities of the four LCA-derived metabolic profiles to estimate 168 
overall cancer risk, specific cancer types risk, cancer mortality and overall mortality, assigning the 169 
reference level to the healthy metabolic profile Class 1 (Tables 3A - 3B). 170 
 171 
Table 3A| Hazard ratios and 95 % confidence interval for the association of LCA-derived metabolic classes and overall 172 
cancer risk and cancer specific risk. 173 
 174 
 Hazard Ratios (95% CI) a Hazard Ratios (95% CI) b 
Cancer Risk: All cancer types   
Number of events 1956 1956 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.09 (0.98 - 1.22) 1.05 (0.94 - 1.17) 
3 - Liver 1.28 (1.10 - 1.50) 1.28 (1.09 - 1.49) 
4 – Inflammation & Iron 1.17 (0.97 - 1.41) 1.17 (0.97 - 1.41) 
Cancer Risk: Buccal cavity and pharynx   
Number of events 34 34 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.79 (0.77 - 4.14) 1.70 (0.73 - 1.17) 
3 - Liver 2.66 (0.96 - 7.35) 2.60 (0.94 - 7.16) 
4 - Inflammation & Iron 3.94 (1.38 - 11.30) 3.77 (1.31 - 10.82) 
10 
 
Cancer Risk: Digestive organs and peritoneum  
Number of events 133 133 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 0.83 (0.62 - 1.11) 0.83 (0.62 - 1.11) 
3 - Liver 2.12 (1.54 - 2.91) 2.12 (1.54 - 2.91) 
4 - Inflammation & Iron 0.86 (0.51 - 1.46) 0.86 (0.51 - 1.46) 
Cancer Risk: Respiratory system   
Number of events 133 133 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.40 (0.94 - 2.08) 1.32 (0.88 -1.96) 
3 - Liver 0.90 (0.44 - 1.82) 0.87 (0.43 - 1.77) 
4 - Inflammation & Iron 1.48 (0.76 - 2.88) 1.46 (0.75 - 2.84) 
Cancer Risk: Skin melanoma   
Number of events 205 205 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 0.78 (0.56 - 1.10) 0.78 (0.56 - 1.11) 
3 - Liver 0.71 (0.40 - 1.26) 0.73 (0.41 - 1.31) 
4 - Inflammation & Iron 0.70 (0.35 - 1.37) 0.70 (0.35 - 1.37) 
Cancer Risk: Breast and genito-urinary organs   
Number of events 655 655 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.19 (0.99 - 1.42) 1.12 (0.94 - 1.33) 
3 - Liver 1.04 (0.80 - 1.37) 1.04 (0.80 - 1.37) 
4 - Inflammation & Iron 1.25 (0.91 - 1.71) 1.25 (0.91 - 1.71) 
Cancer Risk: Brain & nervous system, Thyroids  
Number of events 34 34 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.01 (0.51 - 1.99) 0.96 (0.48 - 1.00) 
3 - Liver 1.01 (0.38 - 2.67) 0.99 (0.38 - 2.59) 
4 - Inflammation & Iron 0.92 (0.28 - 2.99) 0.91 (0.28 - 2.96) 
Cancer Risk: Connective and endocrine tissue  
Number of events 56 56 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 0.65 (0.21 - 1.95) 0.64 (0.21 - 1.94) 
3 - Liver 2.65 (1.00 - 7.02) 2.67 (1.01 - 7.07) 
4 - Inflammation & Iron 3.00 (1.11 - 8.11) 2.96 (1.10 - 8.00) 
Cancer Risk: Lymphatic and hematopoietic tissues: Hodgkin lymphoma, Non-H lymphoma, Leukemia and 
Myeloma 
Number of events 129 129 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.72 (1.15 - 2.56) 1.68 (1.12 - 2.51) 
3 - Liver 1.65 (0.91 - 3.00) 1.68 (0.93 - 3.05) 
4 - Inflammation & Iron 1.23 (0.56 - 2.68) 1.25 (0.57 - 2.73) 
 175 
a Time scale adjusted for age, sex and CCI 176 
11 
 
b Age scale adjusted for age, sex and CCI 177 
 178 
Table 3B| Hazard ratios and 95 % confidence interval for the association of LCA- derived metabolic classes and all 179 
causes death, Cancer death and CVD death. 180 
 181 
 Hazard Ratios (95% CI) a Hazard Ratios (95% CI) b 
All causes death   
Number of events 3158 3158 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.26 (1.16 - 1.37) 1.29 (1.19 - 1.40) 
3 - Liver 1.67 (1.47 - 1.90) 1.70 (1.49 - 1.93) 
4 - Inflammation & Iron 1.21 (1.05 - 1.41) 1.20 (1.04 - 1.40) 
Cancer death   
Number of events 706 706 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.22 (1.02 - 1.45) 1.20 (1.01 - 1.42) 
3 - Liver 1.44 (1.11 - 1.86) 1.46 (1.13 - 1.90) 
4 - Inflammation & Iron 0.93 (0.66 -  1.32) 0.93 (0.66 - 1.32) 
 182 
a Time scale adjusted for age, sex and CCI 183 
b Age scale adjusted for age, sex and CCI 184 
All metabolic profiles increased risk of cancer and mortality compared to Class 1. For instance, 185 
individuals in Class 3 (abnormal liver function profile) had a higher risk of overall cancer (HR: 1.28 186 
(95%CI: 1.10- 1.50)), but also a worse cancer-specific survival and overall survival as compared to 187 
those in Class 1 (Tables 3A – 3B). Class 2 (abnormal lipid profile) and Class 4 (abnormal iron markers 188 
and inflammatory) were positively associated with overall death, while Class 2 was also associated with 189 
cancer–specific death. The results were consistent for both time-scales (Tables 3A – 3B). 190 
 191 
When assessing the risk of specific cancer types, several patterns occurred (Tables 3A –3B).  Individuals 192 
in Class 2 (abnormal lipid markers) presented a higher risk of lymphatic and hematopoietic tissue cancer 193 
(HR: 1.72 (95%CI: 1.15 - 2.56)). There was a greater risk of digestive cancers in individuals in Class 3 194 
(abnormal values of liver enzymes) (HR: 2.12 (95%CI: 1.54 - 2.91)), while individuals in Class 4 195 
(abnormal iron markers and inflammation) were exposed to a higher risk of buccal and oral system 196 
cancers in comparison with the individuals in Class 1 (HR: 3.94 (95%CI 1.38 - 11.30)) (Table 3A). 197 
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Moreover, the connective tissue and endocrine glands cancer risk was higher in individuals grouped in 198 
liver metabolic profile (HR: 2.65 (95%CI: 1.00 - 7.02) and in participants belonging to the iron markers 199 
and inflammation (HR: 3.00 (95%CI: 1.11 - 8.11)). Similar associations were observed when using the 200 
age scale for the multivariable cox proportional hazard regression model (Table 3A – 3B). 201 
 202 
Discussion 203 
We demonstrated that standard of care baseline serum markers when assembled into meaningful 204 
metabolic profiles can help stratify the population for cancer risk, cancer mortality and overall mortality. 205 
More specifically, we observed that abnormal values for markers of the lipid metabolism, liver function 206 
and inflammatory and iron metabolism distinguish participants into metabolic profiles, which are 207 
predictive of long term cancer risk and/or mortality. 208 
 209 
Metabolic profiles 210 
Among the biological pathways addressed in our LCA, abnormalities in the lipid metabolism were the 211 
most common. Hyperlipidemia was present in about a quarter of the study population explaining the 212 
largest abnormal metabolic profile. The weight of the lipid profile in the analysis was consistent with 213 
the reported global prevalence of hypercholesterolemia among adults (37% for males and 40% for 214 
females) as reported in the Global Health Observatory in 2008 estimates by the World Health 215 
Organization (WHO) and the results from the  Swedish population in the WHO MONICA project (46). 216 
Dyslipidemias are associated with higher risk of CVD and other chronic diseases such as cancer, as also 217 
observed in our study (47). Liver dysfunction, iron deficiency and altered inflammatory markers 218 
profiles also distinguished important subgroups in our study population. About 9% of our population 219 
had abnormal values for markers of liver functioning (GGT, AST and ALT), which is similar to the 220 
results obtained in a population-based survey in the United States that estimated abnormal alanine 221 
aminotransferase (ALT) was present in 9% of respondents in absence of viral hepatitis C or excessive 222 
alcohol consumption (48). Moreover, these enzymes are known to be linked to cancer because of their 223 
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role in preserving the intracellular homeostasis of the oxidative stress (49-51), which is concordant with 224 
the results of these analyses. The iron profile and inflammatory markers clustered 6% of individuals in 225 
the study, which was predominantly driven by low levels of serum iron and TIBC, as well as high levels 226 
of CRP and leukocytes. This could potentially point towards anemia of inflammation, a chronic 227 
inflammation presenting low iron values, that occurs because the iron deficiency provides the body with 228 
infection resistance, which demonstrates the tightly connection between the inflammatory response and 229 
the iron and its homeostasis (52). This condition has been reported in more than 30% of cancer patients 230 
at time of diagnosis. 231 
 232 
Metabolic profiles as a risk factor for long term cancer and mortality  233 
The above-described three classes of abnormal metabolic profiles were all associated with an increased 234 
risk of cancer and worse survival, as compared to the healthy class. The findings therefore confirm the 235 
key importance of these metabolisms in the maintenance of the intracellular homeostasis and how their 236 
unbalance can be related with the etiology of cancer disease and mortality (2). The LCA adapted in this 237 
study thus illustrates how a biomarker-wide approach can help assess markers of the blood exposome 238 
in the context of carcinogenesis and mortality (53) (Figure 3). 239 
 240 
More specifically, individuals presenting abnormal liver function markers carried worse outcomes in 241 
terms of overall cancer risk and cancer death, and a positive association with digestive, connective and 242 
endocrine cancers diagnosis. Moreover, the participants with this profile had a higher probability of 243 
overall death. These results are consistent with previous published data. A positive association between 244 
elevated GGT and overall cancer risk, with no interaction of ALT, was found in the AMORIS cohort 245 
previously (24), and it was also reported in other large cohort studies (54, 55). These studies also found 246 
strong associations with elevated levels of GGT and digestive and respiratory cancer incidence. 247 
Elevated GGT has been associated with mortality from all causes, liver disease, cancer and diabetes, 248 
while ALT only showed associations with liver disease death in a large US cohort (56). However, in a 249 
study based on an elderly population it was found that GGT was associated with increased 250 
cardiovascular disease mortality, and ALP and AST with increased cancer-related mortality (57). 251 
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Moreover, a meta-analysis evaluating the associations between liver enzymes and all-cause mortality 252 
found positive independent associations of baseline levels of GGT and ALP with all-cause mortality 253 
(58). In the present study, the liver biomarker profile was positive associated with all the outcomes 254 
studied, suggesting a key role of this pathway in the development of cancer, probably related with its 255 
active role maintaining the intracellular redox regulation. Further investigations are necessary to 256 
establish the potential of the altered liver enzyme profile as a tool for cancer risk stratification. 257 
 258 
Individuals allocated to the lipid profile presented positive associations with cancer mortality, and 259 
overall mortality and higher risk of lymphatic and hematopoietic cancers. The link between 260 
hyperlipidemia and mortality has been studied broadly, with associations with established links for 261 
cancer and all-cause mortality (59-61). The association between lipids and lymphatic and hematopoietic 262 
cancers is more controversial, as other studies found an inverse association for these cancers and high 263 
levels of serum cholesterol (62, 63). However, a systematic literature review from 2016 found no 264 
association (64). 265 
 266 
Participants clustered in the unbalanced iron profile and inflammation had an increased risk of 267 
endocrine, buccal and oral cancers and were observed to have a higher risk of all-causes death. Altered 268 
inflammation and iron metabolisms are key metabolic ‘hallmarks of cancer’ (2, 34, 65).  Our 269 
observation of an association with an increased risk of buccal and oral cancer corroborates previous 270 
findings in AMORIS (34). 271 
 272 
Population heterogeneity and risk stratification: the need for data reduction techniques 273 
The modulation effect of population heterogeneity on the association between potential risks factors 274 
and disease is a new avenue to understand the variability of risk in the population (66). For instance, in 275 
a targeted metabolomics exercise Shan et al. performed a principal component analysis and time to 276 
event analysis identifying metabolic profiles to predict risk of CVD (13). Another study used Monte 277 
Carlo Cross Validation and Lasso logistic regression to evaluate serum biomarkers as an alternative to 278 
fecal immunochemical testing to improve detection of colorectal cancer (11).  In 2010, the European 279 
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Prospective Investigation on Cancer and Nutrition (EPIC) cohort reported that a specific prediagnostic 280 
plasma phospholipid fatty acid profile could predict the risk of gastric cancer (67). As rationalized in 281 
the HELIX project,  these multiple profiling approaches aim to identify groups of individuals in the 282 
population that share a similar exposome that might account for differences on the specific risk of study 283 
(68).Together with these studies, our systematic data integration approach based on LCA demonstrates 284 
the potential of investigating population heterogeneity using metabolic profiling  as risk factors for long 285 
term cancer risk and mortality prediction. However, in order to establish the prediction capability of 286 
these LCA metabolic profiles and implement their use in a clinical setting, further studies to validate 287 
the results whilst allowing to measure sensitivity and specificity, will need to be conducted such as a 288 
nested case-control in AMORIS that could determine the predictive capabilities of the metabolic 289 
profiles to estimate cancer risk and mortality. 290 
 291 
Strengths and limitations 292 
The present study has been conducted in a large and well-defined population, applying a multi-faced 293 
approach covering main biological pathways to assess biomarker profiles that could indicate cancer 294 
risk, cancer survival and mortality.  The major strength of these analyses lies in the innovative avenue 295 
to study population heterogeneity and susceptibility to disease and mortality in a large cohort of 296 
participants with multiple measurements, all measured on fresh blood samples on the same day at the 297 
same clinical laboratory. We included all the markers available in the cohort for a large population 298 
(n>13000), however not every marker of the central metabolic pathways was available in the database 299 
(i.e. Complete Blood Count). Life-style factors established as cancer risk factors such as tobacco 300 
smoking, low physical activity, poor diet, alcohol intake, obesity and hypertension were partially 301 
available in AMORIS which limited their used in the study. To mitigate the lack of some of these 302 
external factors such as BMI, the analyses have been adjusted for Charlson Comorbidity Index which 303 
includes comorbidities such as obesity and hypertension. The lack of others life-style factors such as 304 
alcohol consumption was mitigated by using information on serum biomarkers such as gamma glutamyl 305 
transferase and other liver enzymes.  All participants were selected by analyzing blood samples from 306 
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health check-ups in non-hospitalized individuals from the greater Stockholm area ensuring good 307 
internal validity in the study. Future studies will benefit from a longitudinal approach with repeated 308 
serum markers measurements that will capture the population phenotypic variations in relation to 309 
disease over long periods of time and will help to improve our understanding of the biomarkers’ impact 310 
on carcinogenesis and mortality.  311 
 312 
Conclusion 313 
Our findings support the recently expressed need for a shift from the classical epidemiological approach 314 
of assessing one exposure to a systemic approach with multiple exposures. The LCA adapted in this 315 
study illustrates how a biomarker-wide approach can help assess population susceptibility to disease 316 
and provide insight into disease etiology in the context of carcinogenesis and mortality (Figure 3). Given 317 
the environmental and genetic modulation of metabolic molecules, metabolic profiling based on 318 
standard of care serum markers could become a useful non-invasive predictive signature for risk 319 
stratification and an important area of research for mechanisms and clinical relevance. 320 
 321 
Methods 322 
Study design and study population 323 
The AMORIS study, a large prospective cohort study, has been described in detail elsewhere (19, 21, 324 
22). Briefly, the AMORIS database is based on linkages with the Central Automation Laboratory 325 
(CALAB) database, which analyzed fresh blood samples from subjects from the greater Stockholm 326 
area. All individuals were either healthy individuals referred for clinical laboratory testing as part of a 327 
general health check-up or outpatients between 1985 and 1996. The AMORIS cohort has been linked 328 
to several Swedish national registries such as the National Cancer Register, the Patient Register, the 329 
Cause of Death Register, the consecutive Swedish Censuses during 1970-1990, and the National 330 
Register of Emigration, using the Swedish 10-digit personal identity number. These linkages provide 331 
detail information on demographics, lifestyle, socio-economic status, vital status, cancer diagnosis, 332 
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comorbidities and emigration. The AMORIS study conformed to the declaration of Helsinki and was 333 
approved by the ethics board of the Karolinska Institute. 334 
 335 
From the AMORIS cohort, we included all individuals aged 20 years or older with measurements for 336 
the following serum biomarkers (n=13,615), which were all measured on the same day, using fully 337 
automated methods with automatic calibration performed on fresh blood samples, at the same laboratory 338 
(CALAB) of high quality according to international blinded testing (23) (Appendix Table S1 and S2): 339 
total cholesterol (TC) (mmol/L), triglycerides (TG) (mmol/L), apolipoprotein A-1 (ApoA-I)  (g/L), 340 
apolipoprotein B (ApoB) (g/L),  high density lipoprotein (HDL) (mmol/L), low density lipoprotein 341 
(LDL) (mmol/L), glucose (mmol/L), fructosamine (FAMN) (mmol/L), gamma-glutamyl transferase 342 
(GGT) (IU/L), alanine aminotransferase (ALT) (IU/L), aspartate aminotransferase (AST) (IU/L),  343 
albumin (g/L), leukocytes (WBC) (109 cells/L), C-reactive protein (CRP) (mg/L),  iron (FE) (µmol/L), 344 
total iron binding capacity (TIBC) (mg/dL), creatinine (µmol/L), phosphate (mmol/L) and calcium 345 
(mmol/L). All methods have previously been described (22). 346 
These biomarkers were selected to reflect common metabolic pathways: lipid (TC, TG, ApoA-I, ApoB, 347 
HDL and LDL) and glucose metabolism (Glucose, FAMN), liver function (GGT, ALT and AST), 348 
inflammation (Albumin, WBC and CRP), iron metabolism (FE and TIBC), kidney function (Creatinine) 349 
and phosphate (Phosphate and Calcium). The blood metabolites included in the analysis were all the 350 
standard serum markers available from routine health check-ups. Most of  the markers included have 351 
been previously studied individually in AMORIS, however no systemic integrative approach to 352 
examine the metabolic markers interactions and susceptibility to cancer has been conducted to date (24-353 
35). All participants were free from cancer at time of study entry and none were diagnosed with cancer 354 
within the first three years of follow-up to avoid reverse causation. 355 
 356 
The main exposure variables for the analyses were the above-mentioned metabolic biomarkers, for 357 
which the values were categorized using standardized clinical cut-offs based on recognized medical 358 
criteria to facilitate interpretation of the results (Appendix Table S2). The main outcomes were first 359 
cancer diagnosis, as registered in the National Cancer Register using ICD-9 for the years 1987-1992, 360 
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ICD-O/2 for years 1993-2004 and for year 2005 onwards has been coded in ICD-O/3), and mortality. 361 
As secondary outcomes, we explored those cancer types for which there were more than 30 events 362 
during follow-up. Likewise, cancer mortality was explored. Follow-up time was assessed specifically 363 
for each of the outcomes studied. For cancer diagnosis, follow-up time was defined as time from blood 364 
drawn until date of first cancer diagnosis, death, emigration or study closing date (31st of December 365 
2012), whichever occurred first. The follow-up time for death was described as time from blood drawn 366 
until date of death, emigration or study closing date (31st of December 2012), whichever occurred first. 367 
 368 
Information on the following potential confounders was also incorporated: age, sex and comorbidities. 369 
The latter was quantified using the Charlson Comorbidity Index (CCI) calculated based on data from 370 
the National Patient Register. The CCI comprises 17 disease categories, all assigned a weight. The sum 371 
of an individual’s weights was used to create the CCI ranging from no comorbidity to severe 372 
comorbidity (0, 1, 2, and ≥3) (36).  373 
 374 
Data Analysis 375 
First, we calculated Pearson correlation coefficients to measure the strength of association between 376 
the biomarkers included in the analysis. Pearson’s correlation analyses showed strong correlation 377 
between the different biomarkers in the lipid metabolism (TC, LDL and ApoB (r >0.7); HDL and ApoA-378 
I (r>0.8)). We replaced the individual lipid biomarkers by the established ApoB/ApoA-I ratio and log 379 
(TG/HDL) ratio (20, 23, 37, 38)  to avoid collinearity and to comply with the principle of local 380 
independence as required by latent class analysis (39). Most of the markers were normally distributed 381 
except from the liver biomarkers. 382 
 383 
Latent Class Analysis (LCA) (39, 40) is a model-based clustering method that reduces the dimension 384 
of the data by clustering covariates into latent classes, using a probabilistic model that describes the 385 
data distribution, and it assesses the probability that individuals belong to certain latent classes. LCA 386 
avoids the use of a linear combination or a random distance definition to reduce the number of covariates 387 
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(41) and has recently been employed in health sciences (42, 43). More specifically, we applied LCA to 388 
characterize different classes of individuals based on their metabolic profiles (44) and to evaluate 389 
intrinsic associations between the  biomarkers, using the poLCA package (45) in R statistical 390 
programming language. We first determined the optimal number of LCA-derived classes by executing 391 
step-wise models with different numbers of classes, starting with the null model and adding one extra 392 
class in each model until reaching the total number of biomarkers in the data, while the model kept 393 
converging into a local maximum likelihood. The criterions used for model selection (Akaike 394 
information criterion (AIC), Bayesian information criterion (BIC) and Chi-squared distribution) were 395 
evaluated to estimate the best goodness of fit model and to define the optimal number of LCA-derived 396 
metabolic classes that characterized our dataset. To identify which sets of biomarkers predominantly 397 
explained each latent class, how the classes were distributed across the study population and which 398 
individuals were allocated to each class, we assessed the conditional probabilities, mixed proportions 399 
and class memberships of the best fitted latent class model. 400 
 401 
Once each subject was assigned to its LCA-derived metabolic class, we conducted multivariable Cox 402 
proportional hazard regression to examine whether the LCA-derived metabolic classes were 403 
associated with long term risk of overall cancer as well as specific cancer types. In addition, we 404 
evaluated how the classes were associated with all cause-death and cancer-specific death. All models 405 
were adjusted for age, sex, and CCI. We performed a sensitivity analysis using age as a time-scale, as 406 
this is potentially a strong confounder. Moreover, Schoenfeld residuals were tested to ensure the 407 
proportional hazard assumption of the multivariable cox proportional hazard regression analysis. 408 
 409 
Data management and statistical analyses were performed using Statistical Analysis Systems (SAS) 410 
release 4.3 (SAS Institute, Cary, NC) and R version 3.0.2 (R Foundation for Statistical Computing, 411 





AIC - Akaike information criterion  415 
ALT - Alanine Aminotransferase  416 
AMORIS - Apolipoprotein MOrtality RISk Study 417 
ApoA-I - Apolipoprotein A-1 418 
ApoB - Apolipoprotein B 419 
AST - Aspartate Aminotransferase  420 
BIC - Bayesian information criterion 421 
CALAB -  Central Automation Laboratory 422 
CCI - Charlson Comorbidity Index 423 
CRP - C-reactive protein 424 
FAMN – Fructosamine 425 
FE - Iron 426 
GGT - Gamma-glutamyl Transferase  427 
HDL - High Density Lipoprotein 428 
ICD-9 - International Classification of Diseases 9th Revision 429 
ICD-O/2 International Classification of Diseases for Oncology 2nd Revision  430 
ICD-O/3 International Classification of Diseases for Oncology 3rd Revision  431 
LCA - Latent Class analysis  432 
LDL - Low Density Lipoprotein 433 
SAS - Statistical Analysis Systems  434 
TC - Total Cholesterol  435 
TIBC - Total Iron Binding Capacity 436 
TG - Triglycerides  437 
WBC - Leukocytes 438 
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Figure 1A| Line-graph depicting the goodness of fit indicators AIC and BIC. The model that best 
fits the dataset comprehends of four latent classes as determined by the minimum value reached by 
AIC and BIC criterions before stabilization of the values. The criterion did not converge to a local 





Figure 1B| Line-graph depicting the goodness of fit indicators (X^2(1) (Chi-square). The model that 
best fits the dataset comprehends of four latent classes as determined by the minimum value reached by 
Chi-square. The criterions did not converge to a local maximum from class 12 onwards. 
 
Figure 2| Class Membership Probabilities for abnormal clinical values of the serum markers for the 
four LCA – derived metabolic classes.  The four different biomarker profiles are represented in the 
graph. 
Figure 3| Study statistical pipeline describing the methodology followed in the project. We explored 
the blood exposome using metabolic markers of the population to assess how population heterogeneity 




Additional Files 697 
Table S1.docx| Laboratory fully automated methods with automatic calibration were performed at one accredited 698 
laboratory (CALAB to measure the serum biomarkers examine in the study. 699 
 700 
Table S2.docx| Panel of serum markers describing standard medical cut-offs information.  701 
 702 
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